Nanobiotix’s Laurent Lévy: “We’re creating a new class of medicines and a potential $6bn blockbuster."

Most biotech companies rely on biology, Nanobiotix is betting on physics instead. The company has spent the last two decades pursuing targeted physics-based therapies, that, if successful, could atethe course of medical treatment while generating huge revenues for the company.